. Accumulation of these and other unknown genetic changes is considered to be necessary for tumorigenesis, but none of the known changes can foretell metastatic potential (Fearon, 1994) .
The complex processes of tumour progression include both positive and negative regulatory elements, such as activation of oncogenes and inactivation of tumour-suppressor genes . The adenoma-carcinoma sequence in colorectal cancer is a well-known cascade of multistep genetic events including various mutations, some of which have been characterised (Cawkwell et al., 1994; Fearon, 1994) . Accumulation of these and other unknown genetic changes is considered to be necessary for tumorigenesis, but none of the known changes can foretell metastatic potential (Fearon, 1994) .
It was not long ago that the new human potential metastasis-suppressor gene family, 'non-metastatic' nm23, was identified (Steeg et al., 1988) . nm23-H1 has been mapped to human chromosome locus 17q21.3-22, and the gene encodes a Mr 17 000 protein of unknown function (Backer et al., 1993; . Potential roles for the nm23 protein have been suggested, such as in the formation of a basement membrane, in tumour differentiation and cell proliferation (Caligo et al., 1995; Howlett et al., 1994; Lombardi et al., 1995) .
A down-regulated expression of nm23-H 1, on either mRNA and/or protein level, has been reported in various human cancers (some with highly metastatic activities), such as malignant melanoma (Florenes et al., 1992; Xerri et al., 1994) , squamous cell cancer of the lung (Huwer et al., 1994) , hepatocellular cancer (lizuka et al., 1995) , ovarian cancer (Mandai et al., 1994) and gastric cancer (Nakayama et al., 1993) . Similar findings have been reported for breast cancer (Bevilacqua et al., 1989; Hennessy et al., 1991; Hirayama et al., 1991; Royds et al., 1993; Stahl et al., 1991; Tokunaga et al., 1993) , although this was not the case in a study by SastreGarau et al. (1992) . Mutations and deletions of the nm23 gene have been shown in a number of primary tumours, such as neuroblastomas, lung, breast and renal cancer (Leone et al., , 1993 , but not in prostatic cancer (Brewster et al., 1994) . Taken together, these results suggest that the nm23 gene may have an important role in the mechanism of metastasis in many solid tumour forms.
However, the role of the nm23-H 1 gene in tumour progression and for metastatic potential of colorectal cancer, is not clear. Conflicting observations have been reported on the protein level (Ayhan et al., 1993; Haut et al., 1991; Lacombe et al., 1991; Royds et al., 1994; Tannapfel et al., 1995; Yamaguchi et al., 1993; Zeng et al., 1994) ; on the mRNA level (Haut et al., 1991; Myeroff and Markowitz, 1993; Yamaguchi et al., 1993; Zeng et al., 1994) ; and on the DNA-level (Bafico et al., 1993; Campo et al., 1994; Cawkwell et al., 1994; Cohn et al., 1991; Heide et al., 1994; lacopetta et al., 1994; Okada et al., 1994; Steeg et al., 1991; Wang et al., 1993; Whitelaw and Northover, 1994) .
We have previously explored DNA ploidy, cell proliferative index (Lindmark et al., 1991) and p53 status (Kressner et al., 1996) in colorectal cancer, without being able to detect any substantial correlation to common clinicopathological characteristics and to patient survival time. Nevertheless, continued search for prognostic predictors in colorectal cancer is essential. Thus far, no factors have been identified capable of discriminating between patients truly cured by surgery and patients having subclinical micrometastases in Dukes' stages B and C (Dukes and Bussey, 1958) . If such factors were to be available, additional therapy could be offered to selected patients running a high risk for tumour relapse. Furthermore, selected patients could be included in surveillance programmes.
The main goal in the present study was to evaluate whether the expression of the nm23-HI protein, possibly associated with events occurring later than p53-related events in tumour progression (Fearon, 1994) Lindmark et al. (1991) and Kressner et al. (1996) .
Histopathological evaluation Tumour stage and tumour differentiation Tumour differentiation was assessed according to the WHO recommendations (Morson and Sobin, 1976) , and tumour staging according to Dukes' classification system (Dukes and Bussey, 1958) .
Staining patterns obtained using the anti-nm23-HJ antibody The staining patterns were classified into four types: strong homogeneous intensity, moderate homogeneous intensity, (Figure 1 ). The intraobserver variability was estimated in a second blind evaluation.
Statistics The relation between nm23-H1 staining patterns and the other studied tumour characteristics was determined by x2 analysis, where P < 0.05 was considered significant. Survival curves were constructed using the life-table (actuarial) method (Peto et al., 1977; Lawless, 1982) . (Haut et al., 1991; Lacombe et al., 1991; Yamaguchi et al., 1993; Zeng et al., 1994) . Reduced expression was shown to be associated with progressive tumour stage and distant metastasis in studies by Ayhan et al. (1993) and Tannapfel et al. (1995) . Moreover, Yamaguchi et al. (1993) found that the expression of both mRNA and protein was significantly lower in tumours associated with liver metastasis than in those without such metastasis. In a study by Royds et al. (1994) , there was only a marginal significance between the association of death from colorectal cancer and the nm23 status.
Conflicting conclusions have been drawn in various reports, based on the nm23-H1 expression on the mRNA level. No correlation to the tumour stage was described by Haut et al. (1991) , Myeroff and Markowitz (1993), and Zeng et al. (1994); Yamaguchi et al. (1993) presented a different view in a study.
Allelic deletion and/or mutation of the nm23-H1 gene has, in some papers, been shown to correlate with metastatic progression in colorectal cancer, even if no correlation between nm23-H1 protein and the initial tumour stage could be observed (Campo et al., 1994; Cohn et al., 1991; Wang et al., 1993) . Steeg et al. (1991) claimed that colorectal cancer provides an example where nm23 mRNA levels remain constant, but allelic deletion is correlated with the development of distant metastasis, and furthermore, that this retained nm23 mRNA level may be explained by the fact that the remaining allele compensates for the lost one. No changes on the nm23-HI DNA level in primary colorectal cancer (Bafico et al., 1993; Cawkwell et al., 1994; Whitelaw and Northover, 1994) , or in liver metatases (Heide et al., 1994) Nm23-H1 allelic losses are considered as secondary events, and specific nm23-H 1 mutations have not been observed frequently in colorectal cancer (Bafico et al., 1993 . A lateacting suppressor gene at or near the nm23-H1 locus has been suggested (Cohn et al., 1991) . It has been questioned whether nm23 acts via the traditional recessive suppressor gene model, and alterations, other than reduced nm23 expression, have been proposed as relevant to tumour metastasis .
Based on findings in this colorectal cancer study and on the available literature, it may be concluded that there are tissue-specific differences in the relative importance of the nm23-H1 gene, and that the immunohistochemical expression of nm23-H1 protein has been proven to be unrelated to tumour progression and patient survival time. Thus, this supports the opinon that the role of the nm23-HI genetic alteration must be analysed in the context of association with other genetic changes, rather than with the corresponding protein expression.
